Reckitt Benckiser eyeing up purchase of Pfizer consumer unit
UK-headquartered household and consumer goods firm Reckitt Benckiser, which has only just completed its L1.93 billion ($3.39 billion) acquisition of the Boots company's over-the-counter medicines business, is reportedly set to make a bid for the consumer health care operations of global drug giant Pfizer, which the latter has suggested could be up for sale (Marketletters passim).
According to the UK newspaper the Sunday Times, Reckitt Benckiser has retained Merril Lynch to handle financing of the deal, and it is estimated that it will make an offer of L6.0 billion for the Pfizer unit. However, Pfizer has already made it clear that it is looking for more.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze